Shares of Diploma PLC (LON:DPLM - Get Free Report) rose 0% during mid-day trading on Wednesday . The company traded as high as GBX 4,870 ($65.22) and last traded at GBX 4,862 ($65.11). Approximately 11,753,362 shares were traded during trading, an increase of 1,962% from the average daily volume of 570,027 shares. The stock had previously closed at GBX 4,860 ($65.09).
Diploma Price Performance
The company has a debt-to-equity ratio of 62.17, a current ratio of 2.17 and a quick ratio of 0.80. The stock's fifty day simple moving average is GBX 3,949.28 and its 200-day simple moving average is GBX 4,253.28. The company has a market capitalization of £6.46 billion, a P/E ratio of 55.70, a PEG ratio of 2.82 and a beta of 0.75.
Diploma (LON:DPLM - Get Free Report) last released its quarterly earnings results on Wednesday, May 21st. The company reported GBX 80.20 ($1.07) earnings per share (EPS) for the quarter. Diploma had a net margin of 9.25% and a return on equity of 13.18%. On average, equities analysts forecast that Diploma PLC will post 163.7995512 earnings per share for the current fiscal year.
Insider Activity at Diploma
In related news, insider David S. Lowden bought 750 shares of Diploma stock in a transaction that occurred on Friday, March 21st. The stock was acquired at an average price of GBX 3,928 ($52.60) per share, for a total transaction of £29,460 ($39,453.60). Also, insider Ian El-Mokadem bought 500 shares of Diploma stock in a transaction that occurred on Monday, March 24th. The stock was bought at an average price of GBX 3,948 ($52.87) per share, with a total value of £19,740 ($26,436.32). 0.52% of the stock is owned by corporate insiders.
Diploma Company Profile
(
Get Free Report)
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Diploma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diploma wasn't on the list.
While Diploma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
